Early detection is critical to improving survival rates and treatment outcomes for cancer patients, but traditional approaches such as mammograms, low-dose CT scans, and biopsies, while effective, come with challenges. High costs, accessibility, invasiveness, and the potential for false positives are some of the factors that can lead to delays in diagnosis or unnecessary treatments.
To help overcome these hurdles, BioMark Diagnostics Inc (CSE:BUX, OTCQB:BMKDF) is exploring metabolomics leveraging AI and other complementary technologies with the potential to revolutionize early cancer detection.
Charbone Hydrogen Corporation (TSX-V:CH, OTCQB:CHHYF) continued to advance its green hydrogen initiatives during the first quarter of 2025.
The company on Friday confirmed that all required permits have been secured for the construction of its flagship Sorel-Tracy facility.
Reconnaissance Energy Africa Ltd (TSX-V:RECO, OTCQX:RECAF) (ReconAfrica) said Thursday it is advancing preparations to drill its largest exploration target to date, Prospect I, in Namibia, while expanding its footprint in the Etosha-Okavango basin with a new joint venture in Angola.
CEO Brian Reinsborough said the company remains “excited” about the potential of Prospect I, located on Petroleum Exploration License 073 (PEL 73), and expects the rig to move on site by late June, with spud to follow shortly after.
Pensana PLC (LSE:PRE, OTC:PNSPF) shares strengthened after announcing a new £2 million fund raise.
M&G Investment Management is investing £1 million alongside ‘strategic investors’, with new shares priced at 35p per share.
Petro Matad Limited (AIM:MATD, OTC:PRTDF) shares fell 30% on Friday after the Mongolia-focused operator updated on its outstanding oil payments.
In a statement, the company said that invoices from Block XX’s Heron-1 well production between October and April are “ready for payment”, but PetroChina has asked for confirmation from the authorities that ‘there will be no customs, VAT or tax charges’.
Chill Brands Group PLC (LSE:CHLL, OTCQB:CHBRF) expects its shares will resume trading in the coming weeks, as it told investors that it intends to publish financial results shortly.
Specifically, in a stock market statement, Chill said it expects to publish its audited financial results for the year ended 31 March 2024 in June, and its unaudited interim accounts for the six months to 30 September 2024 shortly after.
Tamboran Resources Corporation has successfully closed the first tranche of its previously announced Private Investment in Public Equity (PIPE) of Common Stock. Proceeds will fund ongoing drilling activity towards plateau production from the proposed Shenandoah South (SS) Pilot Project. The second tranche, if completed, is expected to bring total gross proceeds to approximately US$55.4 million (AU$84.5M).
Under the first tranche, Tamboran issued 2,180,515 shares of Common Stock at US$17.74 per share, raising approximately US$38.7 million before placement agent fees and other offering expenses. Bank of America acted as the sole placement agent.
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) earlier this week began its Phase 2A clinical trial of PTX-100 in patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL). CEO James McDonnell talked with Proactive about the initiation.
The company said the first patient has been dosed in the study, following earlier successful results from a Phase 1B trial. PTX-100 is described as a first-in-class inhibitor of geranylgeranyl transferase-1, targeting the Ras pathway—a signalling mechanism implicated in over 20% of cancers.
Earlier this week, Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) announced that it has received a patent in China for its synthetic anti-infective drug candidates, RECCE 327 and RECCE 529. CEO James Graham joined us to discuss how the patent enhances its global intellectual property position, covering methods of use, administration, and manufacture. The protection extends through 2041.
Ionic Rare Earths Ltd (ASX:IXR, OTC:IXRRF)CEO Tim Harrison joined Proactive earlier this week after the company announced the first shipment of recycled rare earth oxides to Brazil, as part of its strategy to build an integrated and sustainable rare earth supply chain through the Viridion joint venture.
Imugene Ltd has tapped Dr John Byon as chief medical officer (CMO), effective immediately, to lead the company’s clinical development strategy as it progresses its pipeline of immuno-oncology therapies.
Byon is a physician-scientist with deep expertise in cancer immunotherapy, having held senior leadership roles at Fate Therapeutics, Lyell Immunopharma, Juno Therapeutics and Genentech.
Latrobe Magnesium Ltd drawing closer to kick off at its Stage 1 Demonstration Plant in Victoria’s Latrobe Valley, having made progress across operational, regulatory and workforce fronts.
The company has wrapped up all necessary documentation for the Environmental Protection Authority (EPA) and says it is now at a stage where there are no outstanding requirements before ore commissioning can begin.
Solis Minerals Ltd (ASX:SLM, TSX-V:SLMN, OTCQB:SLMFF) is set to begin drilling at its fully owned Chancho al Palo Project in southern Peru. The company has mobilised a diamond drill rig for a 2,500 metre drill program targeting multiple high-priority anomalies identified through surface mapping, sampling, and induced polarisation (IP) surveys.
Drilling will be supported by leading local contractor AKD International and is designed to follow up on fieldwork conducted over the past year, which outlined a corridor of mineralised intrusions associated with alteration and copper oxide mineralisation.